SCA
EGRX

SAC Capital Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

SAC Capital Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-27,288
Closed -$348K – 1100
2014
Q1 		$348K Buy
+27,288
New +$370K ﹤0.01% 1344

Other funds holding EGRX

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

SAC Capital Advisors's EGRX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2014, closing a stake of 27,288 shares — an estimated $348K sold.

SAC Capital Advisors first reported a position in EGRX in Q1 2014 and held it in 1 quarter. The position peaked at $348K in Q1 2014. 28 funds tracked by Wall St. Rank hold EGRX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 27,288 Eagle Pharmaceuticals, Inc. shares in Q2 2014, an estimated $348K.
  • SAC Capital Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Eagle Pharmaceuticals, Inc. position peaked at $348K in Q1 2014.
  • 28 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.